AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytruda

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA approval in muscle-invasive bladder cancer patients who are eligible to receive cisplatin-based chemotherapy, AstraZeneca on Thursday reported positive phase 3 results for its Imfinzi, used alongside Padcev, in those who were cisplatin-ineligible.